ReviewThe Lancet. Infectious diseases2012
Mitigating the threat of artemisinin resistance in Africa: improvement of drug-resistance surveillance and response systems.
Review in The Lancet. Infectious diseases, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 2 syntheses or guidelines pooled it, 83 citations in OpenAlex.
- Phytochemical synergy in artemisia annua herbal tea against malaria: a systematic review of its efficacy and safety in the context of emerging Pfkelch13 resistance.Infectious diseases of poverty · 2026Pooled it
- The geography of imported malaria to non-endemic countries: a meta-analysis of nationally reported statistics.The Lancet. Infectious diseases · 2017Pooled it
- Efficacy of text-message reminders on paediatric malaria treatment adherence and their post-treatment return to health facilities in Kenya: a randomized controlled trial.Malaria journal · 2017Trial
- Community-Centric Malaria Prevention in Sub-Saharan Africa: A Narrative Review of Pathways to Elimination and Global Health Impact.Health science reports · 2026Article
- Safeguarding artemisinin: integrating bioproduction innovation and resistance management for malaria eradication.Malaria journal · 2025Review
- Strategies for mitigating emerging artemisinin-based antimalarial drug resistance in Rwanda: a promising approach for managing therapies in malaria-endemic countries.BMJ global health · 2025Review
- Artemisinin and partner drug resistance markers in Plasmodium falciparum from Tanzanian paediatric malaria patients, 2016-2022.Malaria journal · 2025Article
- Emerging Plasmodium falciparum K13 gene mutation to artemisinin-based combination therapies and partner drugs among malaria-infected population in sub-Saharan Africa.Parasites, hosts and diseases · 2025Review
- The human malaria-Antimicrobial agents and chemotherapy · 2024Review
- Article
- Pharmacopeial quality of artemether-lumefantrine anti-malarial agents in Uganda.Malaria journal · 2023Article
- Implementation and challenges to preventing the re-establishment of malaria in China in the COVID-19 era.Globalization and health · 2022Article
- Development and application of immunoassays for rapid quality control of the antimalarial drug combination artesunate-mefloquine.Journal of pharmaceutical and biomedical analysis · 2022Article
- Combined Transcriptome and Proteome Profiling for Role of pfEMP1 in Antimalarial Mechanism of Action of Dihydroartemisinin.Microbiology spectrum · 2021Article
- Mapping partner drug resistance to guide antimalarial combination therapy policies in sub-Saharan Africa.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Molecular surveillance of antimalarial partner drug resistance in sub-Saharan Africa: a spatial-temporal evidence mapping study.The Lancet. Microbe · 2020Review
- Combination treatment with artemisinin and oxaliplatin inhibits tumorigenesis in esophageal cancer EC109 cell through Wnt/β-catenin signaling pathway.Thoracic cancer · 2020Article
- Prevalence of Molecular Markers of Antimalarial Drug Resistance across Altitudinal Transmission Zones in Highland Western Uganda.The American journal of tropical medicine and hygiene · 2019Article
- Efficacy of Mobile Phone Short Message Service (SMS) Reminders on Malaria Treatment Adherence and Day 3 Post-Treatment Reviews (SMS-RES-MAL) in Kenya: A Study Protocol.Journal of clinical trials · 2019Article
- An inventory of supranational antimicrobial resistance surveillance networks involving low- and middle-income countries since 2000.The Journal of antimicrobial chemotherapy · 2018Review
Corrections and comments
- Commented on by
Authors and funding
12 authors at 8 institutions in 7 countries.
Funding
Abstract
Artemisinin-resistant Plasmodium falciparum malaria has emerged in western Cambodia and has been detected in western Thailand. The situation is ominously reminiscent of the emergence of resistance to chloroquine and to sulfadoxine-pyrimethamine several decades ago. Artemisinin resistance is a major threat to global public health, with the most severe potential effects in sub-Saharan Africa, where the disease burden is highest and systems for monitoring and containment of resistance are inadequate. The mechanisms that underlie artemisinin resistance are not fully understood. The main phenotypic trait associated with resistance is a substantial delay in parasite clearance, so far reported in southeast Asia but not in Africa. One of the pillars of the WHO global plan for artemisinin resistance containment is to increase monitoring and surveillance. In this Personal View, we propose strategies that should be adopted by malaria-endemic countries in Africa: resource mobilisation to reactivate regional surveillance networks, establishment of baseline parasite clearance profiles to serve as benchmarks to track emerging artemisinin resistance, improved data sharing to allow pooled analyses to identify rare events, modelling of risk factors for drug resistance, and development and validation of new approaches to monitor resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.